ArticleBMC cancer2026
Clinical impact of the 21-gene recurrence score on adjuvant treatment selection in elderly patients with hormone receptor-positive, HER2-negative early breast cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe 21-gene recurrence score (RS) assay (Oncotype DX) has become a cornerstone for guiding adjuvant systemic therapy in early-stage hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2−) breast cancer. While randomized trials have established the clinical utility of RS, its real-world application in elderly patients remains controversial, particularly regarding potential age-related bias in treatment decision-making.
methodsWe conducted a retrospective cohort study of 216 consecutive patients with early-stage HR+/HER2 − breast cancer who underwent curative surgery followed by Oncotype DX testing. Patients were stratified by age (elderly, ≥ 65 years; non-elderly, < 65 years). RS distribution and adjuvant treatment patterns were analyzed using both continuous and categorical RS measures. Adjuvant systemic therapy was classified into standard endocrine therapy, enhanced endocrine therapy, and intravenous chemotherapy, and age-related differences were evaluated overall and across RS categories.
resultsElderly patients demonstrated a significantly lower median RS compared with non-elderly patients (11 vs. 15, p = 0.008), with a distinct shift toward lower RS categories (p = 0.039). However, substantial overlap in RS distributions was observed, including the presence of high RS tumors among elderly patients. In the overall cohort, adjuvant treatment patterns did not differ significantly by age (p = 0.884). When stratified by RS category, no significant age-related differences in treatment selection were observed in low- or intermediate-RS groups. Among patients with high RS, intravenous chemotherapy was administered to both elderly and non-elderly patients without a statistically significant difference (p = 0.106).
conclusionsAlthough elderly patients exhibited lower RS values overall, tumors with high genomic risk were observed across age groups. Age-related differences in adjuvant treatment selection were attenuated when treatment decisions were interpreted within RS-defined risk categories, including among patients with high RS. These findings support the continued use of genomic assays to facilitate biologically driven and individualized adjuvant treatment decision-making in elderly patients with HR+/HER2 − early breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.